6 years of revenue, profit, cash flow and balance-sheet history through FY2024, from SEC filings, in JPY as reported — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2024 | ¥8.3B | ¥149M | 27.1% | -0.2% | 15.9% | 1.8% | -¥1.4B | ¥1.9B | ¥329M |
| 2023 | ¥6.8B | ¥115M | 23.0% | -5.7% | 54.7% | 1.7% | -¥768M | ¥1.6B | ¥106M |
| 2022 | ¥7.0B | ¥149M | 27.4% | 1.4% | -250.9% | 2.2% | -¥806M | ¥1.2B | ¥605M |
| 2021 | ¥5.4B | -¥991M | 0.0% | -8.7% | 475.5% | -17.2% | -¥653M | ¥909M | ¥371M |
| 2020 | ¥3.3B | -¥539M | 0.0% | -22.3% | -109.8% | -9.4% | -¥440M | ¥911M | ¥1.4B |
| 2019 | ¥3.9B | ¥17M | 0.0% | 0.9% | 2.9% | 0.4% | ¥464000 | ¥342M | ¥514M |
Over the past 5 years, Medirom Healthcare Technologies Inc.'s revenue has grown 16.3% per year, and net income grown 53.7% per year. These are computed facts, not advice.
As of FY2024, Medirom Healthcare Technologies Inc. reported ¥1.9B of total debt against ¥329M of cash; operating income covered interest expense -0.4×.
In FY2024, gross margin was 27.1%, operating margin -0.2%, and net margin 1.8%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — its annual and interim reports, in JPY as reported (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (annual and interim filings, reported in JPY) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.